Cue Health’s portable, fast COVID-19 test gains FDA emergency approval

Fresh off a $100 million Series C funding round, molecular diagnostics startup Cue Health has more good news – it has received an Emergency Use Authorization (EUA) for its rapid, point-of-care COVID-19 test. The company got a $13 million grant from BARDA in March to help it scale its development and deployment of rapid diagnostics, and its COVID-19 test is obviously a key focus of that effort given the current global pandemic.

Cue’s test is portable, and uses an RNA detection method to confirm the presence of the actual virus in a patient’s system using nasal swab samples. The company

Leave a Reply